Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL14853938 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056533 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL329746 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL10815678 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056827 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9060684 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Arauridine SCHEMBL359587 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL7752140 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1804774 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103502224-A | Flumazenil complexes, compositions comprising same and uses thereof | COERULEUS LTD | 2014-01-08 | — | — | CN | claimed |
| CN-100593250-C | Storage device and semiconductor device | SEMICONDUCTOR ENERGY LAB | 2010-03-03 | — | — | CN | claimed |
| WO-1996028190-A1 | NON-INVASIVE IMAGING OF GENE TRANSFER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0204264-B1 | CONVERSION OF URACIL DERIVATIVES TO CYTOSINE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1990-08-16 | — | — | EP | claimed |
| US-4754026-A | Conversion of uracil derivatives to cytosine derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-28 | — | — | US | claimed |
| EP-0204264-A2 | Conversion of uracil derivatives to cytosine derivatives | Takeda Chemical Industries, Ltd. (JP) | 1986-12-10 | — | — | EP | claimed |
| US-12636369-B2 | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12480117-B2 | Compositions comprising modified circular polyribonucleotides and uses thereof | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025151803-A1 | ALPHAVIRAL ENCRYPTED RNAS AND THEIR METHODS OF USE | AUTONOMOUS THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025151800-A1 | PROGRAMMABLE, RNA EDITOR-CONTROLLED NUCLEIC ACID DOSE AMPLIFIERS AND THEIR METHODS OF USE | AUTONOMOUS THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2003039523-A2 | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES | EXIQON A/S (DK) | 2003-05-15 | — | — | WO | disclosed |
| US-5703056-A | MONITORING THERAPY | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1996028190-A1 | NON-INVASIVE IMAGING OF GENE TRANSFER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-09-19 | — | — | WO | disclosed |
| US-4404368-A | Lyophilized phosphorylated nucleosides | ENS BIOLOGICALS INC. (CA) | 1983-09-13 | — | — | US | disclosed |
| EP-0085084-A1 | COMBINED PREPARATION WITH SYNERGISTIC EFFECT | ROBUGEN GMBH PHARMAZEUTISCHE FABRIK (DE) | 1983-08-10 | — | — | EP | disclosed |
| WO-1983000436-A1 | COMBINED PREPARATION WITH SYNERGIC EFFECT | GAURI, KAILASH, KUMAR | 1983-02-17 | — | — | WO | disclosed |
| EP-0058563-A1 | Lyophilized phosphorylated nucleosides | ens BIO LOGICALS INC. (CA) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | SLC28A1 19/4885SLC28A2 30/4885SLC29A1 16/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | SLC28A1 19/4885SLC28A2 35/4885SLC29A1 31/4885 |
| US-12636369-B2 | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof | USP25, RBM25, TRIM25 | SLC28A1 2395/4885SLC28A2 1737/4885SLC29A1 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.